Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study.

Matteo MegnaLuigi FornaroLuca PotestioMaria Antonietta LucianoMariateresa NocerinoMario DelfinoMaria GuarinoGabriella FabbrociniElisa Camela

Published in: Psoriasis (Auckland, N.Z.) (2022)

Our study found that ADA and ETA biosimilars are effective and safe for the treatment of moderate-to-severe psoriasis in children and the elderly. No statistically significant efficacy and safety differences were found between ADA and ETA biosimilars in both children and the elderly. Geriatric patients displayed a higher discontinuation rate and side effects than the pediatric counterpart even if without approaching statistical significance.

Keyphrases

young adults
end stage renal disease
rheumatoid arthritis
middle aged
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
prognostic factors
clinical trial
peritoneal dialysis
patient reported outcomes